This article is more than 5 years old. Information may no longer be current.

Allergic conjunctivitis treatment market: Slow growth, patent expirations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The research and consulting firm GlobalData’s report on the allergic conjunctivitis treatment market shows minimal growth from $1.37 billion in 2013 to $1.44 billion by 2018.

The report shows marginal expansion across six major markets – U.S., Germany, France, Spain, Italy and the UK – driven by increased disease prevalence and the introduction of three new allergic conjunctivitis therapies, namely AC-170 (Aciex Therapeutics), OTX-DP (sustained-release dexamethasone, Ocular Therapeutix) and Vekacia (cyclosporine A, Novagali), according to the press release.

Alvina To, PhD, GlobalData’s analyst covering neurology and ophthalmology, explained in the press release that these drugs will stimulate market growth and provide alternative choices to physicians.

Also impacting the slow growth are three U.S. patent expirations of Lotemax (loteprednol etabonate, Bausch + Lomb), Patanol (olopatadine, Alcon) and Lastacaft (alcaftadine, Allergan) in 2014, 2015 and 2016, according to the press release.